Occurrence of a multidrug-resistant phenotype in human lung xenografts

J. Mattern, M. Bak* & M. Volm
Department of Experimental Pathology, German Cancer Research Center, Im Neuenheimer Feld 280, D-6900, Heidelberg, FRG.

Summary The intrinsic sensitivity of a panel of 8 human epidermoid lung cancer xenografts to vincristine and actinomycin D has been examined and the cross-resistance patterns of the most vincristine-resistant and actinomycin D-resistant tumour line were tested to a variety of other drugs, including radiation. The results demonstrate that xenograft lines derived from human lung tumours not previously treated with chemotherapy exhibit a similar general pattern of cross-resistance to the drugs vincristine, actinomycin D and Adriamycin as is observed in human cell lines and in animal models selected for resistance to these drugs. It is also shown that intrinsic resistance to vincristine can be partially overcome by verapamil. This may indicate a potential role of this substance in circumventing clinically observed drug resistance.

The current treatment results of epidermoid lung cancer with cytotoxic agents are disappointing. Objectively proven tumour response can be achieved only in a small number of patients and this response is generally short-lived with little or no improvement in survival time. Neither the nature of the intrinsic resistance of tumours which do not respond to treatment nor the acquired resistance that can develop following an initial response to chemotherapy has been well characterized. Studies performed with cultured tumour cell lines and transplantable tumours selected for resistance to a single drug have shown that cross-resistance between antra-cyclines, actinomycins and vinca alkaloids is a common phenomenon. This phenomenon, known as multidrug resistance or pleiotropic resistance, describes the simultaneous expression of cellular resistance to a wide range of structurally unrelated drugs (Biedler & Riehm, 1970; Dano, 1972; Johnson et al., 1978; Kaye & Bowden, 1980). Reduced cellular accumulation of the drugs as a consequence of reduced drug influx or increased drug efflux appears to account for this resistance (Beck, 1984; Riordan & Ling, 1985). Also an increased expression of a high molecular weight, plasma membrane glycoprotein which correlates with the degree of drug resistance, could be identified in multidrug resistant cell lines (for survey see Gerlach et al., 1986). Recently, Bell et al. (1985a, b) detected elevated levels of such membrane proteins in biopsy specimens from patients undergoing therapy for ovarian cancer and sarcomas. These findings suggest that multidrug resistant tumour cells also occur in human malignancies.

The question arises from these and other studies whether multi-drug resistance occurs only in tumours selected for resistance to a single drug or whether this phenomenon can be detected also in tumours not previously treated with chemotherapy.

In the present study we examined the intrinsic sensitivity to vincristine and actinomycin D of eight human tumour xenografts derived from epidermoid carcinomas of the lung and describe the cross-resistance patterns of a vincristine-resistant and sensitive tumour line to a variety of commonly used cytotoxic agents, including radiation.

Materials and methods

Nude mice

NMRI (nu/nu) (nude) female mice, 6–10 weeks old, were purchased from the Breeding Center, Hannover, FRG. The animals were maintained by conventional methods in Makrolon cages at 25°C and 50% humidity. Autoclaved feed and acidified water were provided ad libitum.

Tumours

Eight human epidermoid lung carcinomas established as xenografts in nude mice were used. All tumour lines were not previously treated with chemotherapy and were derived from untreated patients. Their characteristics, including histology and growth rates, are presented in Table 1. At the time of this study, the light microscopical histologic appearance of the 8 tumour lines was epidermoid carcinoma of the lung. Cytogenetic studies revealed a human karyotype. The tumour lines have been maintained by serial s.c. transplantation of minced tumours into the right subaxillary region (0.1 ml/mouse) (Mattern et al., 1985).

Chemotherapy and evaluation of therapeutic effect

After the tumours had reached a mean diameter of 8–10 mm, the tumour-bearing mice were randomized into groups of 5–7 animals each, and treatment with the drugs (as single i.p. dose) or irradiation was started. Each drug was given at the maximum-tolerated dose to the mouse. Vincristine (VCR, Eli Lilly GmbH, Bad Homberg): 2 mg kg⁻¹; actinomycin D (AD, MSD Sharp & Dohme, GmbH): 0.5 mg kg⁻¹; adriamycin (ADM, Farmitalia Carlo Erba GmbH, Freiburg): 10 mg kg⁻¹; 5-fluorouracil (5-FU, Hoffmann-La Roche, AG, Grenzach): 200 mg kg⁻¹; cis-platin (DDP, Bristol-Myers GmbH, Neu-Isenburg): 10 mg kg⁻¹; cyclophosphamide (CTX, Asta-Werke Degussa, Bielefeld): 240 mg kg⁻¹; melphalan (L-PAM, Deutsche Wellcome GmbH, Burgwedel): 12 mg kg⁻¹; verapamil (VER, Stadapharm GmbH, Bad Wibbel): 25 mg kg⁻¹. All agents were injected in a volume of 0.02 ml g⁻¹ body wt. Photon irradiation was performed with Co⁶⁰ gamma rays (Siemens, Erlangen). Dose: 10 Gy.

The tumour growth was followed by measuring two diameters daily with calipers. The tumour weight was calculated for an ellipsoid by the formula V = (a² × b)/2, where a is the length and b is the length in mm. This can be considered a valid estimation of weight in mg, assuming unit density (Geran et al., 1972). The tumour sizes were standardized in the different groups by obtaining relative tumour weight (RW) calculated by the formula RW = Wx/Wo, where Wx is the mean tumour weight at any time given and Wo is the mean initial tumour weight at the start of treatment. The effect of drugs was expressed as a T/C-ratio (mean tumour size of the treated tumour/mean tumour size of control group) × 100. The lowest value was expressed as an optimal T/C (%) for each group.

*Permanent address: National Institute of Oncology, Budapest, Hungary.

Correspondence: J. Mattern.
Received 17 March 1987; and in revised form, 12 June 1987.
Wilcoxon rank sum test was used to compare control groups versus treated groups.

Results

In order to establish human lung tumour lines with different sensitivity to vincristine, samples of human epidermoid lung carcinoma lines which have been established in nude mice and stored in liquid nitrogen were thawed and reimplanted into nude mice. Eight tumour lines grew again, the historical features of these lines are summarized in Table I. All tumours had not received prior chemo- or radiotherapy in the clinical stage or as xenografts in nude mice. Tumour mass doubling times in nude mice ranged between 2.7 and 7.7 days. The therapeutic responses of these 8 human epidermoid lung tumours to a single dose of vincristine and actinomycin D were assessed by plotting changes in relative tumour size versus time and is shown in Figure I. As expected, the tumour lines responded differently to vincristine (left) and actinomycin D (right). Some tumour lines responded very strongly, whereas others showed only little effect. Moreover, the tumour lines which were less responsive to vincristine were also less responsive to actinomycin D, and conversely, the tumour lines which proved to be sensitive to vincristine were also sensitive to actinomycin D. When the effects of vincristine (expressed as optimal T/C values) on the 8 tumour lines are correlated with the effects of actinomycin D, a close relationship can be found (r=0.96). Actinomycin D which is structurally dissimilar to vinca alkaloids shows cross-resistance to vincristine, although the tumour lines were not treated with any of these substances before.

Cross-resistance patterns for the most vincristine-resistant line (HXL 54) and for the most vincristine-sensitive line (HXL 55) are shown in Figures 2 and 3. With the tumour line HXL 54, cross-resistance between vincristine, actinomycin D and adriamycin is apparent whereas collateral sensitivity to all the other agents tested including irradiation is observed. The tumour line HXL 55 shows sensitivity to all drugs tested as well as to irradiation.

To investigate whether the calcium channel blocker verapamil could overcome intrinsic resistance to vincristine or could improve existing sensitivity, experiments were carried out with the resistant tumour line HXL 54 and the sensitive line HXL 55. Both tumour lines were treated simultaneously with 25 mg kg⁻¹ verapamil and 1 mg kg⁻¹ vincristine. The results are shown in Table II. The dose of 25 mg kg⁻¹ verapamil alone causes no inhibition of tumour growth in both tumour lines. Whereas the resistance to vincristine in the tumour line HXL 54 can partially be overcome by the addition of verapamil (P<0.05), the sensitivity of HXL 55 to vincristine cannot be substantially influenced.

Table I Characteristics of eight human epidermoid lung cancer xenografts lines in nude mice ranked according to the sensitivity to vincristine (VCR)

| No. | Tumour line | Differentiation | Tumour doubling time (days) | Optimal T/C (%) |
|-----|-------------|----------------|----------------------------|-----------------|
| 1   | HXL 54     | well           | 6.0                        | 87              |
| 2   | HXL 208    | poorly         | 2.7                        | 72              |
| 3   | HXL 204    | poorly         | 7.7                        | 71              |
| 4   | HXL 163    | moderately     | 5.3                        | 60              |
| 5   | HXL 3      | moderately     | 5.0                        | 58              |
| 6   | HXL 266    | poorly         | 2.5                        | 42              |
| 7   | HXL 182    | moderately     | 7.0                        | 37              |
| 8   | HXL 55     | poorly         | 3.5                        | 4               |

Figure 1 Effect of a single dose of 2 mg kg⁻¹ vincristine (left) and 0.5 mg kg⁻¹ actinomycin D on the tumour size of 8 different epidermoid lung cancer xenograft lines in nude mice.
as a single agent in untreated patients (Bakowski & Crouch, 1983).

However, the question whether cells with a multidrug resistant phenotype are also present in situ in human tumours, is of clinical importance. There are only few clinical data regarding the emergence of multidrug-resistance and it is not clear whether cross-resistance between antibiotics, anthracyclines and vinca alkaloids is a common finding. Attempts to demonstrate the presence of multidrug-resistant cells in human tumours have involved in vitro colony-forming assays in soft agar (Shoemaker et al., 1983) or assays which measure the ability of tumour cells to incorporate labelled precursors in the presence of cytotoxic drugs (Bech-Hansen et al., 1977; Volm et al., 1979).

From our study, it is clear, under the experimental conditions employed, that intrinsic resistance to vincristine is correlated with resistance to actinomycin D. Although the HXL 54 which is a well differentiated tumour with a relatively slow growth rate was found to be more resistant to all the agents tested including irradiation than, for instance, HXL 55 which is poorly differentiated and faster growing, the close relationship between the effects of vincristine and actinomycin D for the eight tumour lines supports the concept of cross-resistance between these two agents. The collateral sensitivity to alkylating agents and to antimetabolites which is often observed in a number of multidrug resistant cell lines, is also found in the resistant tumour line HXL 54 with CTX and DDP but is not so evident with 5-

---

**Figure 2** Cross-resistance patterns of the vincristine-resistant tumour line HXL 54. The points and the bars represent mean values ± s.d. *P* values as evaluated by the Wilcoxon rank sum test on day 10 between treated and control groups: VCR: 0.13; AD: 0.53; ADM: 0.24; 5-FU: 0.03; CTX: 0.0003; DDP: 0.0006 (day 9); L-PAM: 0.0012; Co60: 0.01.

**Table II** Effect of 25 mg kg⁻¹ verapamil and 1 mg kg⁻¹ vincristine on the tumour size of the vincristine-resistant tumour line HXL 54 (left) and the vincristine-sensitive line HXL 55 (right)

|       | HXL 54 |       | HXL 55 |       |
|-------|--------|-------|--------|-------|
|       | T/C (%) | Mean RW | P value | T/C (%) | Mean RW | P value |
| Control | 2.31 ± 0.54⁷ |   |         | Control | 2.67 ± 0.66 |   |
| VER | 95 | 2.19 ± 0.46 |   | VER | 102 | 2.74 ± 0.33 |   |
| VCR | 87 | 2.00 ± 0.23 | *P < 0.05 | VCR | 45 | 0.85 ± 0.26 | NS⁶ |
| VCR + VER | 63 | 1.46 ± 0.25 |   | VCR + VER | 39 | 0.74 ± 0.09 |   |

⁷RW = relative tumours weights on day 6 after treatment; ⁸each results represents mean ± s.d.; ⁹NS = not significant.
FU and L-PAM. Conter and Beck (1984) have shown that the cross-resistance pattern of a VCR-resistant cell line to other agents was dependent on the degree of VCR resistance and that the degree of cross-resistance can vary considerably among the different cell lines, regardless of the selection agent or the extent of primary resistance. Furthermore, comparable degrees of resistance to one drug do not necessarily predict comparable degrees of cross-resistance to other drugs. The tumour line HXL 208 which is also relatively resistant to VCR and AD and reveals a similar growth rate as HXL 55, shows also a collateral sensitivity to CTX (optimal T/C value on day 10: 25%; $P=0.003$). Previously, Merry et al. (1984) reported on the inherent sensitivity of six cell lines established from human gliomas to cytotoxic drugs and could demonstrate a similar pattern of cross-resistance as found in multidrug-resistant cell lines. These results led to the assumption that mechanisms involved in inherent resistance are perhaps related to those found in multidrug resistant cells.

A wide spectrum of drugs, including many that do not possess antitumour activity, have been demonstrated to potentiate the cytotoxic effects of some antineoplastic agents (for survey see Kessel, 1986). Verapamil, a calcium antagonist widely used in cardiological medicine, has been shown to be a potent modifier of vincristine resistance. In our studies, we found that verapamil (25 mg kg$^{-1}$) in vivo is able to increase vincristine cytotoxicity of the resistant line HXL 54, but not of the sensitive line HXL 55. These data are consistent with results of other authors who demonstrated that verapamil increased vincristine cytotoxicity in drug resistant cells in vitro (Tsuroo et al., 1981, 1982). Thus, verapamil is able to potentiate both inherent and induced resistance and this indicates a potential role for verapamil in circumventing clinically observed drug resistance.

In conclusion, our results demonstrate that xenograft lines derived from human lung tumours not previously treated with chemotherapy exhibit a similar general pattern of cross-resistance to the drugs vincristine, Adriamycin and Actinomycin D as is observed in multidrug-resistant human cell lines and in animal tumour models and that the intrinsic resistance to vincristine can be partially overcome by verapamil.

References

BAKOWSKI, D.R. & CROUCH, J.C. (1983). Chemotherapy of non-small cell lung cancer; a reappraisal and a look to the future. Cancer Treat. Rev., 10, 159.

BECH-HANSEN, N.T., SARANGI, F., SUTHERLAND, D.J.A. & LING, V. (1977). Rapid assays for evaluating the drug sensitivity of tumor cells. J. Natl Cancer Inst., 59, 21.
